Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

46.11
+0.71001.56%
Pre-market: 46.250.1400+0.30%07:36 EDT
Volume:1.19M
Turnover:54.73M
Market Cap:7.74B
PE:118.77
High:46.11
Open:44.98
Low:44.75
Close:45.40
52wk High:55.67
52wk Low:26.40
Shares:167.76M
Float Shares:155.00M
Volume Ratio:0.93
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:4.28
PE(LYR):32.24

Loading ...

Alkermes Plc : TD Cowen Raises Target Price to $57 from $50

THOMSON REUTERS
·
Jul 13

Alkermes Price Target Announced at $60.00/share by JP Morgan

Dow Jones
·
Jul 13

Alkermes Says Alixorexton Sustains Wakefulness Gains in Nine-month Narcolepsy Extension Study Interim Analysis

Reuters
·
Jul 13

Alkermes - Alixorexton Generally Well Tolerated at All Doses Tested

THOMSON REUTERS
·
Jul 13

Alkermes - Alixorexton Shows Sustained Improvement on Mwt and ESS at Week 24, Nine Months After First Dose

THOMSON REUTERS
·
Jul 13

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults with Narcolepsy Type 1 and Type 2 in Long-term Extension Study Interim Analysis

THOMSON REUTERS
·
Jul 13

Bank of America Securities Remains a Sell on Alkermes (ALKS)

TIPRANKS
·
Jul 13

Alkermes Plc : JP Morgan Resumes Coverage with Neutral Rating; Target Price $60

THOMSON REUTERS
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

TIPRANKS
·
Jul 09

Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention?

Simply Wall St.
·
Jul 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)

TIPRANKS
·
Jul 08

Alkermes - no Penalties or Further Obligations Owed by Alkermes or Amneal After Agreement Termination - SEC Filing

THOMSON REUTERS
·
Jul 08

Alkermes - Co and Amneal Terminate Authorized Generic Product Supply Agreement on July 6, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 08

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $109,882.02

Reuters
·
Jul 07

The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion

Simply Wall St.
·
Jul 04

Alkermes (ALKS) Gets a Buy from Mizuho Securities

TIPRANKS
·
Jul 02

Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Disposes of USD 463,233 in Common Shares

Reuters
·
Jul 02

Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says

MT Newswires Live
·
Jun 29

Alkermes Cut to Underperform from Neutral by B of a Securities

Dow Jones
·
Jun 29

BofA Securities Downgrades Alkermes to Underperform From Neutral, $38 Price Target

MT Newswires Live
·
Jun 29